Technology
Samsung BioLogics makes strong market debut after Trump victory
Nov. 10, 2016
Samsung BioLogics, a contract manufacturer of biologic drugs under the Samsung Group, made a strong stock market debut Thursday, as its shares were buoyed by rosy expectations for the pharmaceutical industry after Donald Trump’s victory in the US presidential election. Shares of Samsung BioLogics opened at 135,000 won ($117.50) apiece on Korea’s main stock market Kospi, slightly lower than their initial public offering price of 136,000 won. After trading began, the shares continued to rally thro